NeuroQure Obtains Patents of Autism Detection in Newborns

The company's commitment to closing the gap in current technologies demonstrates its desire to improve the lives of children and families affected by autism disorders.

FREMONT, CA: “The exclusive license of patents from UC Irvine has the potential for NeuroQure to bring medical diagnostic tools validated with top-tier publications and issued patents as a functional biomarker diagnostic for the broad ASD spectrum from the lab to market, enabling early intervention and improving children’s lives,” says David Justus, Founder and CEO of NeuroQure. 

NeuroQure, a pioneering biotech startup specializing in gene therapy for neurocognitive disorders, has reached a critical stage in developing its first commercial product. The company has acquired exclusive licensing rights to a patent portfolio from the UC Irvine Center for Autism Research and Translation (CART). 

The intellectual property, developed over seven years with an investment of more than $14 million, serves as the foundation for the development of precise diagnostic tools for autism spectrum disorder (ASD) and related intellectual disabilities.